FOR IN VITRO AND PRE-CLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE
Recovery

TB-500 5mg

5mg recovery research peptide

From€39.00
In Stock · Ships within 48h
Reviews coming soonBe among the first to share your research experience.
Download Certificate of Analysis
  • EU Dispatch
  • CoA Included — Every Batch
  • Discreet Packaging
Purity≥98% HPLC
FormLyophilised Powder
Storage2–8°C
OriginEuropean Stock
DispatchWithin 48h
SKUUL-TB5-5MG
≥98% PureHPLC verified
HPLC TestedDual identity check
EU DispatchShips within 48h
CoA Incl.Every batch
Research Profile

Why TB-500 Fascinates Researchers

TB-500 is a synthetic peptide corresponding to the actin-binding domain of Thymosin β4 (Tβ4), a 43-amino-acid protein originally isolated from thymic tissue. Tβ4 is among the most abundant intracellular proteins in mammalian cells and plays a central role in regulating the actin cytoskeleton — the dynamic structural network that governs cell shape, motility, and division.

Thymosin β4 Fragment & Actin Biology

Thymosin β4 sequesters globular (G-)actin monomers via its LKKTET actin-binding motif, preventing their polymerisation into filamentous (F-)actin. This dynamic equilibrium between G- and F-actin is fundamental to cell migration, wound contraction, and tissue remodelling. TB-500 retains this core β-thymosin actin-binding sequence, making it a research tool for investigating cytoskeletal regulation in contexts where the full 43-residue protein may be impractical.

Thymosin β4 itself is expressed at high levels in platelets, neutrophils, and macrophages — cells at the forefront of injury responses — and is actively secreted to coordinate local tissue repair. Studies have identified Tβ4 and its fragments in wound fluid, suggesting a paracrine signalling role in addition to the well-characterised intracellular actin-sequestering function.

Angiogenesis & Cell Migration Research

A key area of Tβ4 and TB-500 research concerns their pro-angiogenic activity. Goldstein and colleagues documented Tβ4-mediated upregulation of VEGF and promotion of endothelial cell migration and tube formation in Matrigel angiogenesis assays. Activation of integrin-linked kinase (ILK) — a downstream effector of integrin-mediated cell-matrix signalling — has been proposed as a key mechanism, with ILK activation in turn promoting Akt survival signalling and endothelial cell viability under ischaemic conditions.

In cardiac biology, the Srivastava group demonstrated in a landmark 2004 Nature paper that Tβ4 activates ILK and promotes cardiac progenitor cell migration into areas of myocardial injury, representing one of the first demonstrations of a peptide-mediated endogenous cardiac repair mechanism.

Tissue Repair & Research Context

The preclinical literature on Tβ4 and TB-500 spans musculoskeletal, cardiac, corneal, and dermal wound healing models. Consistent findings include accelerated wound closure, reduced inflammatory cell infiltration, and improved organisation of regenerated tissue architecture relative to controls. Anti-inflammatory properties have been documented in models of acute tissue injury, where Tβ4 administration modulates NF-κB pathway activity and pro-inflammatory cytokine production. TB-500 remains a research compound without regulatory approval for human therapeutic use.

This content is for informational purposes only and reflects the state of preclinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.

Manufacturing Standards

Our Quality Commitment

HPLC Verified

Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

≥98% Purity

Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.

Batch Traceability

Each vial is traceable to its synthesis batch, testing date, and analytical records.

Cold Chain Storage

European stock stored at optimal temperature from synthesis to dispatch.

48h EU Dispatch

Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.

CoA Included

Certificate of Analysis issued for every batch, available for download on request.

Download CoA for TB-500 5mg
Peer-Reviewed Literature

Key Scientific Studies

Peer-reviewed research supporting TB-500 investigation.

[01]
Goldstein AL, Hannappel E, Kleinman HK. (2005) — Trends in Molecular Medicine

“Thymosin β4: actin-sequestering protein moonlights to repair injured tissues”

Comprehensive review of thymosin β4 biology, spanning actin-sequestering function, wound healing activity, angiogenesis promotion, and cardiac repair data. Authors contextualise Tβ4 as a multifunctional repair peptide with diverse tissue targets and propose ILK activation as a unifying mechanistic framework for its pro-reparative effects.

View on PubMed
[02]
Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. (2004) — Nature

“Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair”

Landmark paper demonstrating that thymosin β4 activates integrin-linked kinase (ILK) and promotes cardiac progenitor cell migration into injured myocardium. The study documents improved cardiac function following Tβ4 administration in a myocardial infarction model, establishing a molecular mechanism for peptide-mediated cardiac repair and providing one of the earliest demonstrations of Tβ4 as a paracrine repair signal.

View on PubMed
[03]
Philp D, Kleinman HK. (2010) — Annals of the New York Academy of Sciences

“Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide”

Systematic review of animal model studies examining thymosin β4 activity across wound healing, corneal repair, skeletal muscle regeneration, and neurological injury models. Authors document consistent pro-reparative effects across tissue types and discuss the translational implications of the preclinical dataset for research into peptide-mediated tissue restoration.

View on PubMed
[04]
Sosne G, Qiu P, Goldstein AL, Wheater M. (2010) — FASEB Journal

“Thymosin beta 4 inhibits TNF-alpha-induced NF-kappaB activation and cytokine production”

Mechanistic investigation of thymosin β4's anti-inflammatory activity in corneal and epithelial cell models. The study demonstrates suppression of TNF-α-induced NF-κB nuclear translocation and downstream cytokine production, providing a molecular basis for the anti-inflammatory phenotype observed in thymosin β4 wound healing studies.

View on PubMed

All studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.

Common Questions

Research FAQ

Answers to the most frequently asked questions about TB-500.

Same Category

Similar Compounds

Other Recovery research compounds from our catalogue.

Your Longevity Research Guide Awaits

Subscribe to receive new compound profiles, CoA updates, and curated research digests — delivered directly to your inbox.